AIM ImmunoTech (NYSE:AIM) Price Target Cut to $1.00

AIM ImmunoTech (NYSE:AIM) had its target price cut by equities research analysts at Maxim Group from $2.00 to $1.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s price target indicates a potential upside of 271.75% from the company’s current price.

Separately, Ascendiant Capital Markets lowered their price target on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

AIM ImmunoTech Stock Up 1.5 %

Shares of AIM traded up $0.00 during trading hours on Tuesday, reaching $0.27. 321,909 shares of the stock traded hands, compared to its average volume of 254,697. The stock has a fifty day simple moving average of $0.30 and a 200 day simple moving average of $0.36. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.05. AIM ImmunoTech has a 52 week low of $0.21 and a 52 week high of $0.62. The company has a market cap of $13.85 million, a price-to-earnings ratio of -0.42 and a beta of -0.39.

AIM ImmunoTech (NYSE:AIM) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter. AIM ImmunoTech had a negative net margin of 13,952.74% and a negative return on equity of 269.04%. The business had revenue of $0.05 million during the quarter. On average, equities analysts forecast that AIM ImmunoTech will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC purchased a new position in AIM ImmunoTech Inc. (NYSE:AIM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech as of its most recent SEC filing. Hedge funds and other institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).